Your browser doesn't support javascript.
loading
CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yao, Zhenzhen; Gu, Bin; Zhang, Yanming; Qi, Jiaqian; Chen, Jia; Xu, Yang; Chen, Feng; Ma, Xiao; Miao, Miao; Xue, Shengli; Qiu, Huiying; Tang, Xiaowen; Han, Yue; Chen, Suning; Sun, Aining; Yu, Lei; Wu, Depei; Wang, Ying.
Affiliation
  • Yao Z; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Gu B; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Zhang Y; Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, No 62, Huaihai Road (S.), Huai'an, China.
  • Qi J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Chen J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Xu Y; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Chen F; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Ma X; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Miao M; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
  • Xue S; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Qiu H; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Tang X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Han Y; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Chen S; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Sun A; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yu L; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Wang Y; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Bone Marrow Transplant ; 58(1): 103-105, 2023 01.
Article in En | MEDLINE | ID: mdl-36253466
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Hematopoietic Stem Cell Transplantation / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Receptors, Chimeric Antigen / Bridge Therapy Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2023 Document type: Article Affiliation country: China Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Hematopoietic Stem Cell Transplantation / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Receptors, Chimeric Antigen / Bridge Therapy Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2023 Document type: Article Affiliation country: China Country of publication: Reino Unido